Retrospective analysis of cases with HBV reactivation after Hematopoietic Stem Cell Transplantatio
Not Applicable
Completed
- Conditions
- HBV reactivation after hematopoietic cell transplantation
- Registration Number
- JPRN-UMIN000046803
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Not provided
Exclusion Criteria
1) A patient who was confirmed HBs antigen positive before HCT 2) A patient treat by nucleotide analogue before the diagnosis of HBV reactivation 3) A patient who refuses entry to the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method re-reactivation of HBV after cessation of nucleotide analogue
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive HBV reactivation post-hematopoietic stem cell transplantation in JPRN-UMIN000046803?
How do antiviral prophylaxis strategies compare in preventing HBV reactivation after HSCT in observational studies?
Which biomarkers correlate with HBV reactivation risk in patients undergoing allogeneic hematopoietic cell transplantation?
What adverse events are associated with HBV reactivation following HSCT and their management in clinical practice?
What role do nucleoside analogs play in mitigating HBV reactivation post-HSCT in Hokkaido University Hospital's cohort?